{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for alpha root_names_name in Any Name (approximate match)
Status:
Investigational
Source:
NCT01777165: Phase 2 Interventional Completed Acute Kidney Injury
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Modimelanotide is a melanocortinergic peptide drug derived from α-melanocyte-stimulating hormone (α-MSH) which was under development for the treatment of acute kidney injury. Modimelanotide had promising preclinical data, and a Phase II trial in patients undergoing cardiopulmonary bypass surgery showed a reduced incidence of acute kidney injury in subjects that received Modimelanotide. However, a Phase IIb, multicenter study of Modimelanotide in patients with chronic kidney disease who underwent cardiopulmonary bypass surgery failed to show a significant reduction in the incidence of acute kidney injury in subjects who received the drug, both by serum creatinine measurements and by novel biomarkers of tubular injury.
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00572598: Early Phase 1 Interventional Completed Breast Cancer
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02965599: Phase 2 Interventional Terminated Arthritis, Rheumatoid
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Status:
Investigational
Source:
NCT02490774: Phase 2 Interventional Terminated Contraception
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03262389: Phase 2 Interventional Completed Multiple Myeloma
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
FLUDEOXYGLUCOSE is a fluorinated glucose analog. Its 18F radiolabelled form is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging.
Status:
Investigational
Source:
NCT01977443: Phase 2 Interventional Completed Viral Conjunctivitis
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04129619: Phase 2 Interventional Completed Irritable Bowel Syndrome With Diarrhea
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03520543: Phase 1 Interventional Completed Healthy Controls
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03710707: Phase 1 Interventional Completed Parkinson Disease
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
GNE0877, aminopyrazole derivative, is a highly potent, selective, brain-penetrable LRRK2 inhibitor and an investigational drug for Parkinson's disease therapy. It inhibits LRRK2 Ser1292 autophosphorylation in BAC transgenic mice expressing human LRRK2 protein with the G2019S Parkinson’s disease mutation with an IC50 value of 3 nM in vivo. GNE0877 demonstrated metabolic stability, good oral bioavailability (88%) and brain penetration across multiple species.
